GlaxoSmithKline News and Research

RSS

Unemployed and uninsured to have easy access to free medicines from GSK

GlaxoSmithKline (NYSE: GSK) today announced that it is making free medicines easier to obtain for patients who are unemployed, uninsured or struggling to make ends meet.

17 Sep 2009

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu) vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign, The Wall Street Journal reports. The application for GlaxoSmithKline PLC's vaccine is still being considered (Dooren/Favole, 9/15).

17 Sep 2009

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

16 Sep 2009

Linguistic Systems is MBC's first language translation member

Linguistic Systems, Inc. (LSI), a leading provider of language translation services, today announced that it has joined the Massachusetts Biotechnology Council (MBC) as the first language translation member in the organization.

16 Sep 2009

WHO says 3b people worldwide could receive H1N1 vaccine

Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.

16 Sep 2009

Men and healthcare professionals urged to take proactive approach to prostate cancer

As prostate cancer is the third leading cause of cancer death in European men with more than 300,000 men being diagnosed every year, society needs to commit to changing the way the disease is viewed. Therefore a mini-symposium and lunch meeting are organized on 18 September 2009 in Antwerp on the occasion of the European launch of the Proactive Prostates Initiative, organized as part of Urology Week.

14 Sep 2009

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.

11 Sep 2009

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

PEPFAR on Wednesday donated eight computers to Swaziland's Ministry of Health to aid in the country's ability to track the progress of the nation's HIV/AIDS programs, the Swazi Observer reports. According to the newspaper, the computers will be distributed to regional clinics across the country (Masilela, 9/10).

10 Sep 2009

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

To continue the state life science industry’s record-setting growth rate, the North Carolina Biotechnology Center, with the help of statewide partners, is building an addition to its Research Triangle Park headquarters.

10 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

The makers of Aquafresh(R) and Sensodyne(R) introduce a breakthrough technology in toothpaste - new iso-active(R) Foaming Gel. Iso-active has a revolutionary delivery system that disperses active ingredients quickly, penetrating those hard-to-reach areas of the mouth.

8 Sep 2009

CEO Cancer Gold Standard accreditation for Independence Blue Cross

Philadelphia-based Independence Blue Cross has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

8 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

GNA/Peace FM examines the recent creation of a local and international taskforce to help shorten the window of time between the completion of the clinical trial of the RTS,S malaria vaccine - currently being tested across Africa - and licensure and vaccine distribution. According to the news service, scientists recently launched a Phase III trial of the RTS,S vaccine in Kintampo, Ghana, which will include 1,200 children, between the ages of 6-12 weeks and 5-17 months.

5 Sep 2009

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Fox Chase Cancer Center has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

1 Sep 2009

Glaxosmithkline affirms safety of Alli

GSK stands firmly behind the safety and efficacy of alli. Our primary priority is patient health, and we want people to know that there is no evidence that alli causes liver damage.

26 Aug 2009

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.

26 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

GlaxoSmithKline News and Research

Unemployed and uninsured to have easy access to free medicines from GSK

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

Santaris Pharma establishes its operations in the U.S.

Linguistic Systems is MBC's first language translation member

WHO says 3b people worldwide could receive H1N1 vaccine

Men and healthcare professionals urged to take proactive approach to prostate cancer

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

Business vertical-focused learning solutions for the health care industry launched by TIS

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

CEO Cancer Gold Standard accreditation for Independence Blue Cross

Third human clinical trial of LigoCyte's norovirus vaccine started

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Glaxosmithkline affirms safety of Alli

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News